Plain-English translation of NCT06130059 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether colchicine, a low-dose anti-inflammatory medication, can help people with heart failure (specifically a type called HFpEF) improve their ability to exercise and reduce inflammation in their body. Half of the participants will take the medication daily for three months, while the other half will take a placebo pill that looks identical but contains no active drug. Researchers will measure how much this treatment improves exercise capacity and inflammation markers.
Many people with this type of heart failure struggle with poor exercise capacity and have ongoing inflammation that doesn't improve with standard heart medicines. This study is investigating whether reducing inflammation with this medication might help these patients feel stronger and exercise better.
You likely qualify if…
You likely don't qualify if…
You will take one pill by mouth every day for three months—either the active medication or a placebo. You won't know which one you're receiving. At the start and end of the study, you'll come to the clinic for testing that includes an exercise test to measure how far you can walk and how hard you can exercise, blood work to check inflammation levels, and an ultrasound of your heart to see if its structure or function has changed.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States